{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:55:21Z","timestamp":1778586921306,"version":"3.51.4"},"reference-count":86,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.clml.2021.06.003","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T09:40:05Z","timestamp":1623750005000},"page":"741-751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review"],"prefix":"10.1016","volume":"21","author":[{"given":"Laeth L.","family":"George","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saarang R.","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen K.","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asmi","family":"Chattaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zunairah","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2021.06.003_bib0001","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"issue":"82","key":"10.1016\/j.clml.2021.06.003_bib0002","first-page":"1","article-title":"Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response","volume":"10","author":"Abdallah","year":"2020","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.clml.2021.06.003_bib0003","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2016.147","article-title":"Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents","volume":"30","author":"Majithia","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2021.06.003_bib0004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.06.003_bib0005","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Eng J Med"},{"issue":"12","key":"10.1016\/j.clml.2021.06.003_bib0006","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2021.06.003_bib0007","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"issue":"10245","key":"10.1016\/j.clml.2021.06.003_bib0008","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clml.2021.06.003_bib0009","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2021.06.003_bib0010","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1517\/14712598.2011.573476","article-title":"Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy","volume":"11","author":"Ramos","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.clml.2021.06.003_bib0011","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","article-title":"The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens","volume":"28","author":"Guest","year":"2005","journal-title":"J Immunother"},{"issue":"9","key":"10.1016\/j.clml.2021.06.003_bib0012","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.clml.2021.06.003_bib0013","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2021.06.003_bib0014","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0167-5699(99)01547-9","article-title":"T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal","volume":"20","author":"Kali\u0144ski","year":"1999","journal-title":"Immunol Today"},{"key":"10.1016\/j.clml.2021.06.003_bib0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0065-2776(06)90002-9","article-title":"Mechanisms of immune evasion by tumors","volume":"90","author":"Drake","year":"2006","journal-title":"Adv Immunol"},{"issue":"2","key":"10.1016\/j.clml.2021.06.003_bib0016","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jocit.2016.08.001","article-title":"Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: summary and perspective","volume":"2","author":"Smith","year":"2016","journal-title":"J Cell Immunother"},{"issue":"1","key":"10.1016\/j.clml.2021.06.003_bib0017","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1674","article-title":"CAR T-cell therapy in hematologic malignancies: a voyage in progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clml.2021.06.003_bib0018","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2018","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.clml.2021.06.003_bib0019","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"4858","key":"10.1016\/j.clml.2021.06.003_bib0020","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1126\/science.3287617","article-title":"Retroviruses","volume":"240","author":"Varmus","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.clml.2021.06.003_bib0021","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0092-8674(83)90344-6","article-title":"Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus","author":"Mann","year":"1983","journal-title":"Cell"},{"issue":"5259","key":"10.1016\/j.clml.2021.06.003_bib0022","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.clml.2021.06.003_bib0023","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy\u2013how far can we go?","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"7","key":"10.1016\/j.clml.2021.06.003_bib0024","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"issue":"25","key":"10.1016\/j.clml.2021.06.003_bib0025","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"issue":"355","key":"10.1016\/j.clml.2021.06.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2021.06.003_bib0027","article-title":"Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci TranslMed"},{"key":"10.1016\/j.clml.2021.06.003_bib0028","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.clml.2021.06.003_bib0029","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/ajh.25445","article-title":"Toxicities of CD19 CAR-T cell immunotherapy","volume":"94","author":"Hirayama","year":"2019","journal-title":"Am J Hematol"},{"issue":"S1","key":"10.1016\/j.clml.2021.06.003_bib0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2021.06.003_bib0031","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","author":"Sheth","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2021.06.003_bib0032","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.coph.2004.02.009","article-title":"The role of the BAFF\/APRIL system in B cell homeostasis and lymphoid cancers","volume":"4","author":"Mackay","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.clml.2021.06.003_bib0033","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth andimmunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2021.06.003_bib0034","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2021.06.003_bib0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.clml.2021.06.003_bib0036","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Eng J Med"},{"issue":"S1","key":"10.1016\/j.clml.2021.06.003_bib0037","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-136307","article-title":"CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed\/refractory multiple myeloma","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.003_bib0038","series-title":"Oral Presentation\/Abstract Presented at the American Society of Hematology Annual Meeting","article-title":"An allogeneic first-in-human study of the anti-BCMA ALLO-715 and the anti-CD52 ALLO-647 in relapsed\/refractory multiple myeloma","author":"Mailankody","year":"2020"},{"issue":"8","key":"10.1016\/j.clml.2021.06.003_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.clml.2021.06.003_bib0040","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Eng J Med"},{"issue":"10","key":"10.1016\/j.clml.2021.06.003_bib0041","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.06.003_bib0042","series-title":"Presented at: ASH Annual Meeting","article-title":"Clinical results of a multicenter study of the first-in-human dual BCMA and CD19 targeted novel platform fast CAR-T cell therapy for patients with relapsed\/refractory multiple myeloma","author":"Jiang","year":"2020"},{"issue":"S1","key":"10.1016\/j.clml.2021.06.003_bib0043","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2019-129405","article-title":"Efficacy and safety of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Cowan","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2021.06.003_bib0044","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cell Immunother"},{"issue":"S1","key":"10.1016\/j.clml.2021.06.003_bib0045","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1182\/blood-2019-128020","article-title":"Results from the completed dose-escalation of the hematological arm of the phase I think study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapse\/refractory acute myeloid leukemia and myelodysplastic syndrome patients","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2021.06.003_bib0046","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/leu.2011.205","article-title":"T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells","volume":"26","author":"Mihara","year":"2012","journal-title":"Leukemia"},{"issue":"S1","key":"10.1016\/j.clml.2021.06.003_bib0047","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2019-126660","article-title":"Updated results from an ongoing phase 1 clinical study of bb21217 anti-BCMA CAR T cell therapy","volume":"134","author":"Berdeja","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2021.06.003_bib0048","first-page":"489","article-title":"CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q","volume":"90","author":"Liebisch","year":"2005","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.clml.2021.06.003_bib0049","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.003_bib0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.matbio.2013.10.005","article-title":"Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse","volume":"35","author":"Ramani","year":"2014","journal-title":"Matrix Biol"},{"issue":"8","key":"10.1016\/j.clml.2021.06.003_bib0051","first-page":"1637","article-title":"CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am J Cancer Res"},{"issue":"15","key":"10.1016\/j.clml.2021.06.003_bib0052","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","article-title":"Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells","volume":"20","author":"Chu","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.clml.2021.06.003_bib0053","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF71normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"issue":"485","key":"10.1016\/j.clml.2021.06.003_bib0054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2021.06.003_bib0055","first-page":"8","article-title":"NKG2D ligands as therapeutic targets","volume":"13","author":"Spear","year":"2013","journal-title":"Cancer Immun."},{"issue":"12","key":"10.1016\/j.clml.2021.06.003_bib0056","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.clml.2021.06.003_bib0057","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"de Larrea","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.clml.2021.06.003_bib0058","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clml.2021.06.003_bib0059","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.clml.2021.06.003_bib0060","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-Cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.06.003_bib0061","series-title":"Presented at 62nd ASH Annual Meeting","article-title":"Phase 1\/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies","author":"Costello","year":"2020"},{"issue":"1","key":"10.1016\/j.clml.2021.06.003_bib0062","first-page":"120","article-title":"PiggyBac transposon vectors: the tools of the human gene encoding","volume":"5","author":"Zhao","year":"2016","journal-title":"Transl Lung Cancer Res"},{"issue":"S1","key":"10.1016\/j.clml.2021.06.003_bib0063","first-page":"3067","article-title":"CD8+ anti-BCMA CAR T-cells effectively kill human multiple myeloma cells in vitro and in vivo","volume":"130","author":"Lin","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2021.06.003_bib0064","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol Cancer"},{"issue":"18","key":"10.1016\/j.clml.2021.06.003_bib0065","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"65","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"issue":"5319","key":"10.1016\/j.clml.2021.06.003_bib0066","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"276","author":"Bonini","year":"1997","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.clml.2021.06.003_bib0067","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/mt.sj.6300122","article-title":"Engineered human TMPK\/AZT as a novel enzyme\/prodrug axis for suicide gene therapy","volume":"15","author":"Sato","year":"2007","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.clml.2021.06.003_bib0068","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","article-title":"Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy","volume":"94","author":"Griffioen","year":"2009","journal-title":"Haematologica"},{"issue":"215","key":"10.1016\/j.clml.2021.06.003_bib0069","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.clml.2021.06.003_bib0070","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.clml.2021.06.003_bib0071","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1021\/jacs.5b00106","article-title":"Redirection of genetically engineered CAR-T cells using bifunctional small molecules","volume":"137","author":"Kim","year":"2015","journal-title":"J Am Chem Soc"},{"issue":"23","key":"10.1016\/j.clml.2021.06.003_bib0072","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1158\/1078-0432.CCR-12-1449","article-title":"Redirecting gene-modified T cells toward various cancer types using tagged antibodies","volume":"18","author":"Tamada","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6258","key":"10.1016\/j.clml.2021.06.003_bib0073","doi-asserted-by":"crossref","first-page":"aab4077","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.clml.2021.06.003_bib0074","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cam4.3624","article-title":"Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and\/or refractory myeloma","volume":"10","author":"Yan","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2021.06.003_bib0075","series-title":"Presented at 62nd ASH Annual Meeting","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study","author":"Lin","year":"2020"},{"key":"10.1016\/j.clml.2021.06.003_bib0076","series-title":"Presented at 62nd ASH Annual Meeting","article-title":"Two-year follow-up of investigator initiated phase 1 trials of the safety and efficacy of fully human anti-BCMA CAR T Cells (CT053) in relapsed\/refractory multiple myeloma","author":"Hao","year":"2020"},{"key":"10.1016\/j.clml.2021.06.003_bib0077","series-title":"Presented at 62nd ASH Annual Meeting","article-title":"Results from lummicar-1: a phase 1 study of fully human B-cell maturation antigen-specific CAR T cells (Ct053) in Chinese subjects with relapsed and\/or refractory multiple myeloma","author":"Chen","year":"2020"},{"key":"10.1016\/j.clml.2021.06.003_bib0078","series-title":"Presented at 62nd ASH Annual Meeting","article-title":"Results from lummicar-2: a phase 1b\/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in patients with relapsed and\/or refractory multiple myeloma","author":"Kumar","year":"2020"},{"key":"10.1016\/j.clml.2021.06.003_bib0079","series-title":"Presented at 62nd ASH Annual Meeting","article-title":"An anti-BCMA CAR T-cell therapy (C-CAR088) shows promising safety and efficacy profile in relapsed or refractory multiple myeloma","author":"An","year":"2020"},{"issue":"15","key":"10.1016\/j.clml.2021.06.003_bib0080","doi-asserted-by":"crossref","first-page":"S8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J Clin Oncol"},{"issue":"S1","key":"10.1016\/j.clml.2021.06.003_bib0081","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-140156","article-title":"Two-year follow-up of investigator-initiated phase 1 trials of the safety and efficacy of fully human anti-BCMA CAR T Cells (CT053) in relapsed\/refractory multiple myeloma","volume":"136","author":"Hao","year":"2020","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2021.06.003_bib0082","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2019.37.15_suppl.2535","article-title":"The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single domain antibody as antigen recognition domain","volume":"37","author":"Han","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2021.06.003_bib0083","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.clml.2021.06.003_bib0084","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"19","key":"10.1016\/j.clml.2021.06.003_bib0085","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"PNAS"},{"issue":"15","key":"10.1016\/j.clml.2021.06.003_bib0086","doi-asserted-by":"crossref","first-page":"8020","DOI":"10.1200\/JCO.2018.36.15_suppl.8020","article-title":"Remission observed from a phase I clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed\/refractory multiple myeloma","volume":"36","author":"Liu","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:20Z","timestamp":1761871100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021002081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":86,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2152265021002081"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.06.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}